EUROPÄISCHE KOMMISSION ERTEILT ZULASSUNG FÜR IMDYLLTRA® VON AMGEN FÜR DIE BEHANDLUNG VON KLEINZELLIGEM LUNGENKREBS IM FORTGESCHRITTENEN STADIUM
RegulatoryapprovedIMDYLLTRAPositive
AI Analysis
Summary
European Commission approved Amgen's IMDYLLTRA for extensive-stage small cell lung cancer based on Phase 3 DeLLphi-304 trial showing 40% reduction in mortality risk versus chemotherapy.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
European Commission approval for IMDYLLTRA for treatment of extensive-stage small cell lung cancer
Importance:8/10
Sentiment:
0.85
regulatory approvalEuropeoncologysmall cell lung cancerPhase 3 data
Related Companies
Read the original article
Published by PR Newswire Biotech on June 3, 2026 7:33 PM